Quick Facts

• A therapeutic option for the treatment of serious infections caused by specific susceptible Gram-negative bacteria.
• Indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in the context of cystic fibrosis (via inhalation).

---

Colina Spezial is authorized for use in the management of certain bacterial infections. It serves as a therapeutic option for patients with serious infections caused by specific susceptible Gram-negative organisms, such as Enterobacter aerogenes, Escherichia coli, and Klebsiella pneumoniae.

This medication is typically reserved for situations where alternative, more commonly prescribed antibiotic treatments are not considered suitable or appropriate due to resistance or other clinical factors. Its role is often as a last-resort agent in the treatment of these challenging infections.

Additionally, Colina Spezial is indicated for the chronic management of pulmonary infections that are associated with Pseudomonas aeruginosa in individuals who have cystic fibrosis. Its use in this patient population assists in controlling the long-term presence of this pathogen in the lungs.

Prescribing decisions for this medication should always be informed by the specific bacteria involved, susceptibility testing, and professional clinical guidelines.

Colina Spezial is authorized for use in adults and children aged 2 years and above for the symptomatic relief of acute gastrointestinal issues. The official regulatory profile strictly defines which populations are ineligible or restricted from using the medicine.

---

Absolute Contraindications The medicine is contraindicated in patients with known hypersensitivity to the active ingredients, Diosmectite and aluminum/magnesium salts. Use is strictly prohibited for individuals with conditions posing a systemic risk from the mineral components; this includes patients with severe renal failure, those on dialysis, and those with intestinal obstruction or severe chronic constipation. Furthermore, it is contraindicated in rare hereditary sugar intolerances.

Population Restrictions Use is explicitly not recommended in children below 2 years of age for the treatment of acute diarrhea, as dictated by national regulatory authorities. The medicine is also officially not recommended for use by pregnant women or those who are breastfeeding, placing these groups in a high-restriction category. Patients with pre-existing conditions like Inflammatory Bowel Disease or a risk of hypophosphatemia require special consideration.

Interactions with other medicines and products

Official regulatory documentation on Colina Spezial, an adsorbent and antacid combination, confirms interactions are primarily due to physicochemical interference in the gastrointestinal tract, which affects the systemic exposure of other oral medications. These interactions are categorized based on adsorption and chelation by the Smectite, Aluminium, and Magnesium components.

Documented Interaction Patterns

• Reduced Bioavailability: The co-administration of Colina Spezial is documented to reduce the absorption and therapeutic exposure of several medicinal product categories, including Bisphosphonates, Tetracycline Antibiotics, and Fluoroquinolone Antibiotics.
• Timing Separation Rule: To mitigate this reduction in exposure, official labeling requires that all other oral medications be administered with a mandatory time separation, generally at least two hours before or four hours after Colina Spezial, though specific separation rules apply to certain drugs like the antiretroviral Delavirdine.
• Contraindicated Additive Effects: Co-administration with the cation-exchange resin Sodium Polystyrene Sulfonate presents a formal interaction-related restriction due to the potential for severe intestinal complications, including colonic necrosis, according to documented warnings.
• Population-Specific Accumulation: For patients with impaired renal function, the interaction profile notes an increased risk of systemic accumulation of both magnesium and aluminium ions, which can lead to toxicity if clearance is compromised.
• Food/Supplement Interaction: Co-ingestion with Ascorbic Acid (Vitamin C) or citrate-containing substances is documented to potentially increase the systemic absorption of Aluminium from the antacid component.

Chemical Neutralization of Gastric Acidity

This domain addresses the drug's rapid, chemical action in the stomach, where the Aluminium and Magnesium salts engage in a stoichiometric acid-base reaction with hydrogen ions ( H^+) and hydrochloric acid. This process directly consumes existing acid, leading to a quick elevation of the gastric pH, thereby diminishing acid-mediated chemical irritation and sensory nerve activation in the gastric mucosa.

Intestinal Adsorption and Mucosal Barrier Formation

This mechanism is driven by Dioctahedral Smectite, a layered clay mineral that acts as a non-specific adsorbent in the intestinal lumen. Smectite physically binds various irritants, including enterotoxins, viruses, and excess water, while simultaneously forming a stabilizing physical barrier over the mucosal epithelium. By reducing the luminal fluid and irritant load, this action modulates the fluid balance and forms a physical barrier on the intestinal lining.

Complementary Peripheral Dual Mechanism

Colina Spezial's core mechanism is the additive, non-systemic modulation of the gastrointestinal tract, targeting two distinct physiological processes at two separate anatomical sites. The antacid component modulates pH in the stomach, while the adsorbent modulates fluid and irritants in the intestine. This segregated, complementary dual action provides a mechanistic breadth, modulating both upper and lower tract physiological processes through purely physical-chemical interactions confined to the lumen.

Colina Spezial is used according to two distinct administration protocols, which are determined by the intended site of action. The medicine is supplied as a powder for injection equivalent to 150 mg of colistin base activity (CBA). This powder must first be reconstituted with sterile water before any use.

For systemic infections, the medication is administered via intravenous (IV) infusion. This protocol is initiated with a single loading dose ranging from 2.5 to 5 milligrams per kilogram (mg/kg) of CBA. The loading dose is immediately followed by a daily maintenance dose of 5 mg/kg CBA, which must be delivered in two to four equally divided doses throughout the 24-hour period. The IV infusion process requires the dose to be delivered slowly over a controlled duration of 30 to 60 minutes.

A critical procedural constraint is the need for dose modification based on renal function. For all patients with renal impairment, the total daily dose must be reduced according to the patient’s calculated creatinine clearance (CL). Furthermore, administration is governed by special handling rules, including the requirement that the solution must not be mixed with certain other antimicrobial agents in the same IV container due to physical incompatibility. For chronic pulmonary infections, Colina Spezial is administered via the inhalation route, typically as part of a long-term management strategy.

Research Evidence / Overview of Studies for Colina Spezial

---

Evidence for Use in Chronic Pulmonary Infections (Cystic Fibrosis)

Research for the inhaled component of Colina Spezial was evaluated in Randomized Controlled Trials (RCTs) and long-term registry studies. These studies primarily included adults and children (typically age 6 and older) with Cystic Fibrosis (CF) who had established colonization of the P. aeruginosa bacterium. The research examined outcomes reflecting daily functioning or activity level, specifically measurements of the forced expiratory volume in one second ( FEV1), which is a standard functional measure monitored by researchers. Studies monitored the frequency and severity of episodic or acute changes—known as pulmonary exacerbations—which require additional medical attention.

Non-inferiority trials examined patterns in lung function measurements over intermediate durations, where the study's goal was to show similarity to other established treatments. However, research is limited in providing clear insight into its use in the youngest pediatric populations, particularly those under the age of 6. Long-term follow-up data tracking the durability of the response over several years is not fully established from randomized controlled settings.

---

Evidence for Use in Serious Acute Bacterial Infections

The use of this medicine for serious bacterial infections was evaluated in cohort studies, often examining critically ill patients with severe infections caused by multi-drug-resistant Gram-negative bacteria. The research primarily focused on outcomes related to systemic or functional imbalance, including measurements of bacterial clearance (microbiological eradication) and overall clinical response. Studies monitored patient outcomes like hospital discharge status and 28-day mortality rates.

Because this medicine was evaluated in research contexts involving complex or multi-drug-resistant infections, the historical pattern of antibiotic use has resulted in a situation where comparative data from that period are scarce. Findings were mixed regarding outcomes like mortality, and sample sizes were modest in many comparative trials, limiting the generalizability of the findings.

---

Evidence for Relief of Gastrointestinal Symptoms

The component used for acute diarrhea was evaluated in research exploring how adsorbent properties function in the gut. This evidence is drawn from short-term RCTs and systematic reviews. Research examined outcomes describing episodic or acute changes, such as the number of stool depositions per day and the total duration of the diarrheal episode. For the antacid component, the evidence relies heavily on pharmacological studies that examined the measurement of immediate acid-neutralizing capability.

Key Studies & References Aluminum Hydroxide and Magnesium Hydroxide: MedlinePlus Drug Information

Common questions about Colina Spezial (FAQ)

Q: What is Colina Spezial used for?

A: Colina Spezial is typically used to help relieve symptoms associated with certain gastrointestinal discomforts, such as:

• Acute and chronic diarrhea, including traveler's diarrhea
• Pain associated with digestive issues, like irritable bowel syndrome (IBS)
• Bloating and discomfort due to excess gas

Q: How does Colina Spezial work?

A: Colina Spezial's mechanism of action involves several ingredients that work together in the gastrointestinal tract:

• Dioctahedral Smectite (Smectite): This natural clay binds to toxins, bacteria, and viruses in the gut, which can help to reduce the severity and duration of diarrhea. It also coats the lining of the digestive tract, offering a protective barrier.
• Dicyclomine: An antispasmodic agent that relaxes the muscles in the stomach and gut (intestine), which helps to relieve sudden muscle contractions (spasms) that cause abdominal cramps and pain.
• Dimethicone: An anti-foaming agent that helps to break up gas bubbles in the gut, allowing for easier passage and relieving bloating.

Q: Can Colina Spezial be taken with other medications?

A: It is important to separate the dose of Colina Spezial from other oral medications. Due to the presence of Dioctahedral Smectite, which can bind to other substances in the gut, taking Colina Spezial at the same time as other medicines can potentially reduce the absorption and effectiveness of those medications.

Always consult your doctor or pharmacist about all the medications and supplements you are currently taking to determine the proper timing for each dose.

Q: What are the common side effects of Colina Spezial?

A: The most common side effects of Colina Spezial may include:

• Gastrointestinal effects: Constipation, bloating, or excessive gas (flatulence).
• Nervous System effects: Drowsiness, dizziness, or blurred vision (due to the dicyclomine component).
• Other common effects: Nausea, vomiting, and dry mouth.

If any of these side effects persist, worsen, or cause significant discomfort, contact your healthcare provider.

Q: Who should not take Colina Spezial?

A: Colina Spezial should be avoided by individuals with certain medical conditions, including:

• Known allergy to any of the ingredients (Dioctahedral Smectite, Dicyclomine, Dimethicone, or excipients like Mefenamic Acid).
• Obstructive diseases of the digestive tract (e.g., intestinal obstruction, paralytic ileus).
• Glaucoma or myasthenia gravis.
• Severe kidney or liver impairment.
• Unstable cardiovascular disease.
• Infants under 6 months of age should not take products containing Mefenamic Acid and Dicyclomine.

Always inform your doctor about your full medical history before starting Colina Spezial.

How to Store and Dispose of Colina Spezial

Storage and disposal instructions for Colina Spezial (Colistimethate Sodium) are dictated by regulatory labeling to maintain drug stability.

Official Storage Requirements

Product Form	Temperature Range	Stability Period
Unopened Powder	Controlled Room Temperature (20 C to 25 C)*	Until Expiry Date
Reconstituted Solution	Refrigerated (2 C to 8 C)	Maximum 7 days

*Excursions permitted between 15 C and 30 C.

The unopened lyophilized powder must be kept in its original container at room temperature. The reconstituted solution must be stored under refrigeration for a maximum of seven days, and any unused portion must be discarded after this period.

Child Safety and Disposal

Colina Spezial must be stored out of the sight and reach of children.

Unused or expired product must not be thrown into household trash or wastewater. Medicines must be disposed of through a pharmacist or according to local regulations for pharmaceutical waste.